Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-002472-16 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| CRS Clinical Research Services Mannheim GmbH | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This diagnostic study will be performed to investigate the performance of the urea cycle in healthy subjects, asymptomatic carriers of Urea Cycle Disorders (UCD) mutations and subjects with genetically proven urea cycle disorders. The ureagenesis rate will be measured by 13C incorporation assay, a method for in vivo measurement of urea cycle performance with stable isotopes.
In this diagnostic study CCD09, the urea metabolism in UCD subjects (patients and carriers) and healthy subjects of different age and sex will be assessed by measurement of the incorporation of 13C from orally taken sodium [1,2-13C]-acetate into urea by 13C stable isotope ratio detection. The aim of the study is to determine the 13C urea production and to quantify the total urea production in healthy subject, gene defect carrier or patient as marker for the functioning of the urea cycle. Since there are still only few data available using this specific method for measurement of urea cycle performance, the aim of this study CCD09 is to gain additional results on the 13C assay. To this end, comparison will be made between 13C urea production observed in healthy subjects, UCD patients, and asymptomatic mutation carriers.
An evaluation of this study may also enable the treating physician to better judge the severity of disease and the future risk of metabolic decompensations in patients as well as the potential risk for so far asymptomatic carriers.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| oral administration of Sodium [1,2-13C]-Acetate | Other | single dose of 0.55 mg/kg 13C-Acetate given orally of via a naso-gastric tube |
| Measure | Description | Time Frame |
|---|---|---|
| Formation of 13C-urea in plasma | 0 - 240 Minutes |
| Measure | Description | Time Frame |
|---|---|---|
| Vital signs | blood pressure, heart rate, temperature and respiratory rate at enrollment and after completion | 0-240 min |
| Complete blood count without differential | at enrollement |
Not provided
Inclusion Criteria:
All study groups:
• Written informed consent given by subjects or his/her parents/legal guardians who are able to understand and follow instructions related to the study
Group 1 Healthy Volunteers:
Group 2 Symptomatic UCD patients with genetically confirmed CPSD, OTCD, ASSD, or ASLD:
Age: 0 - 65 years
Group 3 Asymptomatic carriers of UCD mutations:
Group 4:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Georg F Hoffmann, Prof Dr med | Universitätsklinikum Heidelberg Klinik für Kinderheilkunde I | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CRS Clinical Research Services GmbH (Phase I Unit) | Mönchengladbach | 41061 | Germany | |||
| Medizinische Hochschule Hannover, Klinik für Kinderheilkunde |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Adverse events | 0-240 mins |
| Ammonia, Amino acids, Urea in serum | 0-240 min |
| CRP | at enrollment |
| Venous lactate and blood gases: pH, pCO2, pO2, bicarbonate | at enrollment |
| Blood glucose | 0 - 240 min |
| pH and bicarbonate | 20 and 60 mins after administration |
| Hanover |
| 30625 |
| Germany |
| Universitätsklinikum Heidelberg Klinik für Kinderheilkunde I | Heidelberg | D-69120 | Germany |
| Universitätsklinikum Münster, Zentrum für Kinder- und Jugendmedizin | Münster | 48149 | Germany |
| ID | Term |
|---|---|
| D056806 | Urea Cycle Disorders, Inborn |
| ID | Term |
|---|---|
| D020739 | Brain Diseases, Metabolic, Inborn |
| D001928 | Brain Diseases, Metabolic |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D000592 | Amino Acid Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided